Compare
InMed Pharmaceuticals Inc. vs Procyon Corp vs BullFrog AI Holdings, Inc. vs Lexaria Bioscience Corp.
| Latest fiscal year | InMed Pharmaceuticals Inc. INM | Procyon Corp PCYNLast annual report: year ended 2024-06-30 | BullFrog AI Holdings, Inc. BFRG | Lexaria Bioscience Corp. LEXX |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2024-06-30 | 2025-12-31 | 2025-08-31 |
| Revenue | n/a | $4.98M | $116.7K | $705.9K |
| Revenue growth (YoY) | n/a | +6.4% | n/a | +52.0% |
| Gross margin | n/a | 78.1% | 18.8% | 99.6% |
| Operating margin | n/a | -4.6% | n/m | n/m |
| Net margin | n/a | -6.8% | n/m | n/m |
| Net income | -$12.56M | -$341.1K | -$6.50M | -$11.90M |
| EPS (Diluted) | -$3.12 | -$0.04 | -$0.63 | -$0.66 |
| Operating cash flow | -$8.64M | -$61.3K | -$5.52M | -$10.45M |
| Free cash flow | n/a | -$125.2K | n/a | -$10.48M |
| Cash & equivalents | n/a | n/a | $2.18M | n/a |
| Total assets | $3.03M | $3.20M | $2.81M | $4.18M |
| Total liabilities | $1.96M | $917.1K | $672.0K | $1.57M |
| Shareholders' equity | $1.08M | $2.29M | $2.14M | $2.99M |
| Return on year-end equity | n/m | -14.9% | -304.2% | -398.1% |
| Shares outstanding | 5.34M | 8.12M | 11.42M | 19.56M |
Revenue, most recent five fiscal years
| Fiscal year | InMed Pharmaceuticals Inc. | Procyon Corp | BullFrog AI Holdings, Inc. | Lexaria Bioscience Corp. |
|---|---|---|---|---|
| Latest | $4.94M Ended 2025-06-30 | $4.98M Ended 2024-06-30 | $116.7K Ended 2025-12-31 | $705.9K Ended 2025-08-31 |
| 1 year earlier | $4.60M Ended 2024-06-30 | $4.69M Ended 2023-06-30 | n/a | $464.3K Ended 2024-08-31 |
| 2 years earlier | $4.14M Ended 2023-06-30 | $4.84M Ended 2022-06-30 | $65.0K Ended 2023-12-31 | $226.2K Ended 2023-08-31 |
| 3 years earlier | $1.09M Ended 2022-06-30 | $4.72M Ended 2021-06-30 | $10.0K Ended 2022-12-31 | $255.4K Ended 2022-08-31 |
| 4 years earlier | n/a | $4.33M Ended 2020-06-30 | n/a | $722.7K Ended 2021-08-31 |